National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$32.00
add to cart

Rights & Permissions

topleft topright

Challenges for the FDA: The Future of Drug Safety, Workshop Summary (2007)
Board on Health Sciences Policy (HSP)

Citation Manager

Pray, Leslie, Robinson, Sally. "5 Enhancing Postmarket Safety Monitoring." Challenges for the FDA: The Future of Drug Safety, Workshop Summary. Washington, DC: The National Academies Press, 2007.

Please select a format:

BibTeX EndNote RefMan


Page
33
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Challenges for the FDA: The Future of Drug Safety - Workshop Summary

Adverse Event Reporting System (AERS) database, which comprises three datasets: adverse event data reported voluntarily through MedWatch (generally by physicians, other health care practitioners, and consumers), mandatory periodically reported data from product manufacturers, and mandatory 7- and 15-day expedited report data from manufacturers following notification of a serious and unexpected adverse event. While this passive surveillance system may be capable of detecting rare serious adverse events, it has several limitations, including profound underreporting, biased reporting, and difficulties in attributing an adverse event to a specific drug. Additionally, when analyzing postmarket epidemiological data collected through passive surveillance, it is difficult to know just how many people have taken a drug (i.e., to determine a denominator), it is difficult to know how many events occurred (i.e., to determine the numerator) because of underreporting, and therefore it is difficult to conclude the rate at which an event would take place (e.g., event x would occur in 1 of every 100,000 persons).

Discussion at the symposium focused on how to enhance the current postmarket safety monitoring system by implementing the recommendations of the IOM report listed above, including upgrading AERS, developing an active surveillance system based on automated health care databases, and building internal epidemiological and informatics capacity at the FDA. Multiple panelists expressed the view that rejuvenating the passive surveillance system and augmenting it with an active system would be a specific feasible next step toward a stronger and more effective drug safety system.

FDA INITIATIVES FOR IMPROVING DRUG SAFETY MONITORING1

Revamping the AERS System

Dr. Dal Pan described several initiatives to enhance the FDA’s current postmarket safety surveillance system. In response to Recommendation 4.1 of the IOM report (improving the generation of new safety signals and hypotheses), the Center for Drug Evaluation and Research (CDER) plans to upgrade to AERS II by adding functionalities that will allow for signal tracking, signal management, and data mining capability. Although the project is currently unfunded in the 2007 budget, the agency is evaluating system requirements and estimates the system could be operational in about 2 years once funded.

1

This section is based on the presentation of Gerald Dal Pan, Director, Office of Surveillance and Epidemiology, CDER, FDA.

Page
33